Asthma is a unique form of chronic respiratory disease characterized by reversible airway obstruction and pulmonary inflammation. It represents one of the most common chronic inflammatory diseases affecting an estimated 300 million people worldwide with an expected increase to 400 million by 2025. The sharply rising prevalence and incidence of asthma causes global concern both in the developed as well as in developing countries.
“In order to elucidate the mechanism of how SCRT modulates the allergic response, we evaluated the immunomodulatory effects of SCRT in a murine model of asthma induced by a house dust extract containing cockroach allergens and endotoxin,” explained Jiyoun Kim, PhD, a research assistant professor of pathology and laboratory medicine at BUSM. “In this study multiple aspects of pulmonary inflammation were examined including the production of inflammatory mediators and the pulmonary recruitment of inflammatory cells,” he added.
The researchers found SCRT treatment significantly reduced airway hyper-reactivity as measured by both whole body plethysmography and direct measurement of airway resistance. The researchers report that the immune response of pulmonary inflammation was significantly inhibited by SCRT treatment as demonstrated by reduced plasma IgE antibody levels and improved lung histology. SCRT significantly reduced the number of neutrophils in the bronchoalveolar (BAL) fluid and also significantly reduced the BAL levels of CXC chemokines both expressed as part of the immune response, providing a potential mechanism for the reduced inflammation.
This study was supported by grants from the National Institutes of Health and the Oriental Medicine R&D Project of the Ministry of Health & Welfare of the Republic of Korea.
About Boston University School of Medicine
Originally established in 1848 as the New England Female Medical College, and incorporated into Boston University in 1873, Boston University School of Medicine today is a leading academic medical center with an enrollment of more than 700 medical students and more than 800 masters and PhD students. Its 1,246 full and part-time faculty members generated more than $335 million in funding in the 2009-2010 academic year for research in amyloidosis, arthritis, cardiovascular disease, cancer, infectious disease, pulmonary disease and dermatology among others. The School is affiliated with Boston Medical Center, its principal teaching hospital, the Boston and Bedford Veterans Administration Medical Centers and 16 other regional hospitals as well as the Boston HealthNet.
— 30 —
Contact: Gina M. Digravio, 617-638-8491, [email protected]